sr 33557 has been researched along with quinidine in 1 studies
Studies (sr 33557) | Trials (sr 33557) | Recent Studies (post-2010) (sr 33557) | Studies (quinidine) | Trials (quinidine) | Recent Studies (post-2010) (quinidine) |
---|---|---|---|---|---|
50 | 3 | 1 | 6,608 | 387 | 594 |
Protein | Taxonomy | sr 33557 (IC50) | quinidine (IC50) |
---|---|---|---|
Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | 6.4 | |
Cholinesterase | Homo sapiens (human) | 1.23 | |
ATP-dependent translocase ABCB1 | Mus musculus (house mouse) | 10 | |
ATP-dependent translocase ABCB1 | Homo sapiens (human) | 3.32 | |
Cytochrome P450 2D26 | Rattus norvegicus (Norway rat) | 2.8 | |
Cytochrome P450 2D6 | Homo sapiens (human) | 0.3532 | |
Potassium voltage-gated channel subfamily A member 5 | Homo sapiens (human) | 7.3 | |
Cholinesterase | Equus caballus (horse) | 7.37 | |
Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | 6.4 | |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.7882 | |
Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | 6.4 | |
Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | 6.4 | |
Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | 6.9 | |
Potassium voltage-gated channel subfamily D member 2 | Rattus norvegicus (Norway rat) | 2.2 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
1 other study(ies) available for sr 33557 and quinidine
Article | Year |
---|---|
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |